An observational study in Spinal Cord Injuries, Neurogenic Bladder Dysfunction and Degenerative Cervical Spinal Stenosis, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by University of Zurich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Spinal Cord Injuries by University of Zurich — 7 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · University of Zurich.
Among the 24 studies in Spinal Cord Injuries by University of Zurich, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2023, is one of 10 observational ones, and was the 22nd registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →7 of the 24 studies in Spinal Cord Injuries by University of Zurich are open now, in 1 country. Recruiting first, the newest first:
University of Zurich · Sites in Switzerland
Ages 18–80 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18–80 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Ages 18–75 · Healthy volunteers
University of Zurich · Sites in Switzerland
Ages 18–75
By country, each count listing its studies:
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2004; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 225 is above the median of 60 across 333 observational studies indexed under Spinal Cord Injuries.
Median enrollment 64 across the 14 interventional studies, 204 across the 10 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
3 of the studies in Spinal Cord Injuries by University of Zurich that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01571531University of ZurichEuropean Multicentre Study of Human Spinal Cord Injury | 2026-12 |
| NCT03053791University of ZurichDeep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait | 2026-12 |
| NCT03772548University of ZurichCNS Changes Following SCI | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Spinal Cord Injuries by University of Zurich, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Building on recent improvements, state-of-the-art functional MRI will be applied as an advanced diagnostic tool for the lumbosacral cord in spinal cord injury (SCI) patients to characterize the remaining neuronal activity of the motor and sensory neurons. Alterations in the activity pattern will reveal the effect upon task-related spinal cord activity of the lower motor neurons and sensory neurons undergoing trauma-induced neurodegeneration, at a spatial specificity that has not been possible so far. Results of this study will be of crucial importance because SCI patients can only profit from regeneration-inducing therapies if spinal neuronal function is preserved below the level of lesion.
The participants will be recruited from the primary care clinic as well as via flyers distributed at hospital waiting rooms and patient support organisations.
Healthy controls will be recruited via public announcements and via flyers distributed at the primary care clinic and two universities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients additionally need to fulfil the following study-specific inclusion criteria:
Cross-sectional study:
Longitudinal study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cross-sectional study: lumbosacral functional fMRI
Activations in the gray matter of the lumbosacral cord, as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state). Spatiotemporal components of the BOLD signal as well as the couplings and anti-couplings between these components
Time frame: Baseline only
Longitudinal study: lumbosacral functional fMRI
Activations in the gray matter of the lumbosacral cord, as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state). Spatiotemporal components of the BOLD signal as well as the couplings and anti-couplings between these component
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: brain functional MRI
Activations in the cortical and subcortical areas of the brain as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state)
Time frame: Baseline only
Longitudinal study: brain functional MRI
Activations in the cortical and subcortical areas of the brain as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: diffusion MRI in the spinal cord
Directional diffusivities in the spinal cord (units of mm2/s)
Time frame: Baseline only
Cross-sectional study: diffusion MRI in the spinal cord
Fractional anisotropy in the spinal cord (unitless)
Time frame: Baseline only
Longitudinal study: diffusion MRI in the spinal cord
Directional diffusivities in the spinal cord, measured (units of mm2/s)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: diffusion MRI in the spinal cord
Fractional anisotropy in the spinal cord (unitless)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: structural MRI in spinal cord
Cross-sectional areas of the spinal cord gray and white matter (units of mm2)
Time frame: Baseline only
Longitudinal study: structural MRI in spinal cord
Cross-sectional areas of the spinal cord gray and white matter (units of mm2)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: magnetic resonance neurography of the lumbosacral plexus
Thickness of nerves and nerve roots (units of mm2)
Time frame: Baseline only
Cross-sectional study: magnetic resonance neurography of the lumbosacral plexus
Nerve entry points into the spinal cord (for determining neurological levels)
Time frame: Baseline only
Longitudinal study: magnetic resonance neurography of the lumbosacral plexus
Thickness of nerves and nerve roots (units of mm2)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: magnetic resonance neurography of the lumbosacral plexus
Nerve entry points into the spinal cord (for determining neurological levels)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: diffusion MRI in the brain
Directional diffusivities in the brain (units of mm2/s)
Time frame: Baseline only
Cross-sectional study: diffusion MRI in the brain
Fractional anisotropy in the brain (unitless)
Time frame: Baseline only
Longitudinal study: diffusion MRI in the brain
Directional diffusivities in the brain (units of mm2/s)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: diffusion MRI in the brain
Fractional anisotropy in the brain (unitless)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: structural MRI in the brain
Cortical thickness (units of mm)
Time frame: Baseline only
Cross-sectional study: structural MRI in the brain
Volumes of the brain gray and white matter (units of mm3)
Time frame: Baseline only
Longitudinal study: structural MRI in the brain
Cortical thickness (units of mm)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: structural MRI in the brain
Volumes of the brain gray and white matter (units of mm3)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: nerve conduction study
Latencies of F waves (units of ms). Period between initial stimulation and F wave elicitation in the tibial and peroneal motor nerves.
Time frame: Baseline only
Cross-sectional study: nerve conduction study
Amplitudes of F waves in the tibial and peroneal motor nerves (units of microV)
Time frame: Baseline only
Cross-sectional study: nerve conduction study
Duration of F waves in the tibial and peroneal motor (units of ms)
Time frame: Baseline only
Longitudinal study: nerve conduction study
Latencies of F waves (units of ms). Period between initial stimulation and F wave elicitation in the tibial and peroneal motor nerves.
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: nerve conduction study
Amplitudes of F waves in the tibial and peroneal motor nerves (units of microV)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: nerve conduction study
Duration of F waves in the tibial and peroneal motor (units of ms)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: motor evoked potentials (MEP)
Latencies (units of ms)
Time frame: Baseline only
Cross-sectional study: motor evoked potentials (MEP)
Amplitudes (units of mV)
Time frame: Baseline only
Longitudinal study: motor evoked potentials (MEP)
Latencies (units of ms)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: motor evoked potentials (MEP)
Amplitudes (units of mV)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: American Spinal Injury Association Impairment Scale (AIS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
AIS quantifies the severity of the spinal cord injury. AIS (ASIA Impairment Scale) grades from A-E, whereas grade A (complete spinal cord injury) is worse than grade E (no impairment)
Time frame: Baseline only
Cross-sectional study: Lower Extremities Motor Scale (LEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)
Time frame: Baseline only
Cross-sectional study: Upper Extremities Motor Scale (UEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total UEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)
Time frame: Baseline only
Cross-sectional study: Light touch (LT) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
The LT score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of light touch sensation. It consists of a 2-point scale (0=absent sensation; 1=altered (impaired or partial sensation, including hyperesthesia); 2 = normal or intact sensation) for each dermatome and body site. The lowest and highest possible LT score for one body site is 0 and 56, respectively
Time frame: Baseline only
Cross-sectional study: Pin prick (PP) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
The PP score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of pin prick discrimination. It consists of a 2-point scale (0=absent discrimination; 1=altered (impaired or partial discrimination); 2 = normal or intact discrimination) for each dermatome and body site. The lowest and highest possible PP score for one body site is 0 and 56, respectively
Time frame: Baseline only
Longitudinal study: American Spinal Injury Association Impairment Scale (AIS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
AIS quantifies the severity of the spinal cord injury. AIS (ASIA Impairment Scale) grades from A-E, whereas grade A (complete spinal cord injury) is worse than grade E (no impairment).
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: Lower Extremities Motor Scale (LEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: Upper Extremities Motor Scale (UEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total UEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: Light touch (LT) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
The LT score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of light touch sensation. It consists of a 2-point scale (0=absent sensation; 1=altered (impaired or partial sensation, including hyperesthesia); 2 = normal or intact sensation) for each dermatome and body site. The lowest and highest possible LT score for one body site is 0 and 56, respectively
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: Pin prick (PP) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
The PP score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of pin prick discrimination. It consists of a 2-point scale (0=absent discrimination; 1=altered (impaired or partial discrimination); 2 = normal or intact discrimination) for each dermatome and body site. The lowest and highest possible PP score for one body site is 0 and 56, respectively
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: Graded and Redefined Assessment of Strength, Sensation and Prehension (GRASSP)
GRASSP measures sensorimotor and prehension function through three domains (strength, sensation and prehension) which are important in describing arm and hand function. The total GRASSP score ranges from 0 to 116 points, where a higher score indicates a better outcome
Time frame: Baseline only
Longitudinal study: Graded and Redefined Assessment of Strength, Sensation and Prehension (GRASSP)
GRASSP measures sensorimotor and prehension function through three domains (strength, sensation and prehension) which are important in describing arm and hand function. The total GRASSP score ranges from 0 to 116 points, where a higher score indicates a better outcome
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: European Multicenter Study about SCI (EMSCI) pain questionnaire
The EMSCI pain questionnaire rates various aspects of pain (e.g., current pain intensity, mean and maximal pain intensity during the last week before the assessment, location and quality of pain, intensity of allodynia and paresthesia). Pain intensity is quantified on an 11-point numeric scale (0=no pain; 10=worst imaginable pain)
Time frame: Baseline only
Longitudinal study: European Multicenter Study about SCI (EMSCI) pain questionnaire
The EMSCI pain questionnaire rates various aspects of pain (e.g., current pain intensity, mean and maximal pain intensity during the last week before the assessment, location and quality of pain, intensity of allodynia and paresthesia). Pain intensity is quantified on an 11-point numeric scale (0=no pain; 10=worst imaginable pain)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: sympathetic skin response including hand, sole and perineum recordings
Latencies (units of ms)
Time frame: Baseline only
Cross-sectional study: sympathetic skin response including hand, sole and perineum recordings
Amplitudes (units of microV)
Time frame: Baseline only
Longitudinal study: sympathetic skin response including hand, sole and perineum recordings
Latencies (units of ms)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: sympathetic skin response including hand, sole and perineum recordings
Amplitudes (units of microV)
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: Spinal Cord Independence Measure (SCIM III)
The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.
Time frame: Baseline only
Longitudinal study: Spinal Cord Independence Measure (SCIM III)
The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Cross-sectional study: Walking index for Spinal Cord Injury (WISCI)
WISCI is an ordinal 20-point scale (0=unable to stand and/or participate in walking; 20=ambulates with no devices, with brace and no assistance) to assess walking function
Time frame: Baseline only
Longitudinal study: Walking index for Spinal Cord Injury (WISCI)
WISCI is an ordinal 20-point scale (0=unable to stand and/or participate in walking; 20=ambulates with no devices, with brace and no assistance) to assess walking function
Time frame: Change from baseline at 2-month, 6-month, and 12-month
Longitudinal study: International Prostate Symptom Score (IPSS) (only in patients with neurogenic lower urinary tract dysfunction)
The IPSS score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible"
Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)
Longitudinal study: Qualiveen questionnaire (only in patients with neurogenic lower urinary tract dysfunction)
Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL)
Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)
Longitudinal study: Urinary Symptom Profile (USP) (only in patients with neurogenic lower urinary tract dysfunction)
The USP score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic)
Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)
Longitudinal study: Overactive Bladder (ICIQ-OAB) questionnaire (only in patients with neurogenic lower urinary tract dysfunction)
International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life ICIQ-OAB-QoL is a 26-item questionnaire evaluating quality of life (QoL) in patients with overactive bladder. Scores range from 25-160, with greater values indicating increased impact on quality of life
Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)
Started Jan 2023 (actual). Primary completion is estimated for Aug 2028, 67 months after the start.
Of 124 non-industry observational studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 74. This study's planned 67 months is above that.
Counting every sponsor, half of 135 studies reached it within 39 months; a quarter within 16 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2027 → Aug 2028 and completion Aug 2027 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.